However, no studies have been performed to develop a lipid vesicle targeting LOX, combined with chemotherapy-delivery to evaluate its efficacy compared to standard clinical treatment available for breast cancer patients (e.g., epirubicin). Here, LOX is linked to breast carcinoma.